View Press Releases
-
Industry Leading RBQM Event Returns for 2025
CluePoints, the premier sponsor of RBQMLive and provider of leading statistical and AI-driven software solutions, has announced the full agenda and expert speaker line up for the 4th annual, award-winning event, RBQMLive.
Jun 2, 2025
-
BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement
BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement
Jun 1, 2025
-
Linus Health Study Champions Person-Centered Brain Health Assessments
Linus Health Study Champions Person-Centered Brain Health Assessments
Jun 1, 2025
-
Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research
Orbitrap Astral Zoom and Orbitrap Excedion Pro deliver increased speed and sensitivity to set a new performance benchmark for high-resolution, accurate mass spectrometry
Jun 1, 2025
-
1upHealth Launches Prior Authorization Solution and Technology Partnerships to Support CMS Electronic Prior Authorization Mandate for Health Plans
-
Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director
The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics
May 28, 2025
-
Ambience Healthcare's AI Platform Surpasses Clinician Performance by 27% in Medical Coding, Powered by New OpenAI Breakthrough
-
Latest Nature Communications Study: AI-Enabled Development of Next-Generation ENPP1 Inhibitors for Innate Immune Modulation by Insilico Medicine
Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI in drug discovery. Unlike direct STING agonists, ISM5939 precisely modulates the STING pathway within tumor tissues by targeting ENPP1, thereby restoring local immune activation and enhancing anti-tumor immune responses. For the first time, ENPP1 inhibitors have been shown to overcome dual resistance to immune checkpoint inhibitors and chemotherapy, offering a new therapeutic hope for patients with refractory tumors. Since the start of 2025, this marks Insilico Medicine’s third AI-driven drug discovery study published in a Nature sub-journal. Immune checkpoint inhibitors have transformed cancer treatment, providing clinical benefits for a wide range of malignancies. However, only ~10-35% of patients on these treatments achieve a meaningful and durable response, underscoring the urgent need for innovative therapeutic strategies.
May 28, 2025
-
Association for Molecular Pathology Releases Series of Reports Defining Core Bioinformatics Competencies for Clinical Diagnostic Laboratories
AMP announced the release of a three-part series of papers on core bioinformatics capabilities for professionals in clinical molecular diagnostic labs.
May 26, 2025
-
Nuclera and Cytiva collaborate to accelerate characterization of proteins for drug development
● Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions ● Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions ● Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies
May 27, 2025
-
Sapio Sciences Appoints Gordon McCall as Chief Operating Officer to Drive Global Operational Excellence
Sapio Sciences, the science-aware™ lab informatics platform, today announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.
May 26, 2025
-
START and OneOncology Partner To Expand Access to Early Phase Oncology Trials
This partnership will launch three new START research sites to bring early phase trials closer to patients in major U.S. communities.
May 26, 2025
-
Neurogen Biomarking Announces Partnership with Aranscia
-
Pythia Biosciences and Miraomics to Build a High-Quality Single-Cell Database for Drug Research and AI/ML Acceleration
Pythia Biosciences and Miraomics today announced their collaboration to develop Pythiomics—a rich, high-quality and harmonized single-cell omics database designed to accelerate discoveries and AI/ML development in drug research.
May 21, 2025
-
4D Path Expands Scientific Advisory Board with Global Leaders in Oncology and Pathology
4D Path, a company dedicated to personalizing cancer care through its unprecedented approach to predicting tumor response, recently convened its Scientific Advisory Board (SAB), bringing together an exceptional group of oncology, pathology, and translational research leaders, each deeply committed to advancing precision oncology and translating innovation into patient impact.
May 19, 2025
-
Astoriom Expands Global Footprint for Sample Stability Storage Services
Growth in dedicated sample stability facilities at Tramore (Ireland) site to meet demand for flexible, regulatory-compliant storage solutions
May 19, 2025
-
Onvida Health and Ambience Healthcare Partner to Enhance Patient Care and Revolutionize Clinical Workflows with AI Technology
-
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate strategic update.
May 14, 2025
-
Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy
-
Zymo Research to Host BioFestival at Johns Hopkins University, Empowering Scientific Innovation and Sustainability
My name is Nora Beik, and I am reaching out from Zymo Research to share our latest press release announcing the upcoming BioFestival at Johns Hopkins University, a campus event dedicated to accelerating innovation, celebrating sustainability, and supporting early-career researchers. BioFestival is a growing initiative led by Zymo Research in partnership with top-tier academic institutions, with the goal of empowering the next generation of scientists. This latest installment—hosted in collaboration with Johns Hopkins University—highlights Zymo Research’s ongoing commitment to serving as a trusted partner to academia and a leader in sample preparation for life sciences. We invite you to read the full press release here: https://www.zymoresearch.com/blogs/press-releases/biofestival-johns-hopkins-university We would greatly appreciate it if you would consider sharing this news with your readers. If you require any additional information, high-resolution images, or would like to arrange an interview with one of our experts, please do not hesitate to reach out. I look forward to the opportunity to collaborate with your team. Thank you for your time and consideration.
May 14, 2025